<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">However, because the epidemiological situation in the world is changing rapidly, literally daily, the following chemical entities of umifenovir 
 <bold>7</bold>, agent EIDD-2801 
 <bold>8</bold>, ribavirin 
 <bold>9</bold>, ruxolitinib 
 <bold>10</bold>, ingavirin 
 <bold>11</bold>, azithromycin 
 <bold>12</bold>, ivermectin 
 <bold>13</bold> and danoprevir 
 <bold>14</bold> (
 <xref rid="fig1" ref-type="fig">Fig.Â 1</xref>B) must be considered in ongoing trials.
</p>
